Sugi Predict

Sugi Predict / Compounds / SCHEMBL6181641

SCHEMBL6181641

SCHEMBL6181641

CC(C)(C)C1(O)c2ccc(Cl)cc2CCc2cccnc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FNTA P49354 6/20 0.52
▸ FNTB P49356 6/20 0.52
▸ HRH1 P35367 5/20 0.37
▸ SLC6A15 Q9H2J7 3/20 0.37
▸ PTAFR P25105 2/20 0.37
▸ LMNA P02545 3/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ CHRM2 P08172 2/20 0.37
▸ ABCB1 P08183 2/20 0.37
▸ CHRM3 P20309 2/20 0.37
▸ TBXA2R P21731 2/20 0.37
▸ HRH2 P25021 2/20 0.37
▸ HTR2A P28223 2/20 0.37
▸ OPRK1 P41145 2/20 0.37
▸ HTR2B P41595 2/20 0.37
▸ SLC6A3 Q01959 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ KCNH2 Q12809 2/20 0.37
▸ ADRB2 P07550 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8880225 0.81 FNTA (0.53) FNTAFNTBHRH1SLC6A15PTAFR
SCHEMBL4457894 0.74 MAPK1 (0.53) FNTAFNTBHRH1SLC6A15SMN1; SMN2
SCHEMBL32668926 0.74 MAPK1 (0.53) FNTAFNTBHRH1SLC6A15SMN1; SMN2
SCHEMBL8878464 0.72 FNTA (0.43) FNTAFNTBHRH1SLC6A15PTAFR
SCHEMBL24592167 0.72 FNTA (0.52) FNTAFNTBHRH1SLC6A15PTAFR
SCHEMBL30101891 0.72 FNTA (0.52) FNTAFNTBHRH1SLC6A15PTAFR
SCHEMBL8786099 0.69 FNTA (0.42) FNTAFNTBHRH1SMN1; SMN2DRD2
SCHEMBL18994396 0.69 FNTA (0.45) FNTAFNTBHRH1LMNAMEN1
SCHEMBL14384091 0.69 HRH1 (0.56) FNTAFNTBHRH1SLC6A15LMNA
SCHEMBL31612796 0.68 FNTA (0.43) FNTAFNTBHRH1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1123931-B1 Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases SCHERING CORP (US) 2005-06-01 — — EP disclosed
US-20030055065-A1 Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases BISHOP W ROBERT (US) 2003-03-20 — — US disclosed
US-20020068742-A1 Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases BISHOP W ROBERT (US) 2002-06-06 — — US disclosed
US-6365588-B1 AS ANTINEOPLASTIC AGENT AND A POTENTIATING SCHERING CORPORATION 2002-04-02 — — US disclosed
EP-0723540-B1 TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES SCHERING CORP (US) 2001-12-12 — — EP disclosed
EP-1123931-A1 Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases SCHERING CORPORATION (US) 2001-08-16 — — EP disclosed
US-6242458-B1 INHIBITING FARNESYL PROTEIN TRANSFERASE IN A HUMAN SCHERING CORPORATION 2001-06-05 — — US disclosed
EP-0723540-A1 TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES SCHERING CORPORATION (US) 1996-07-31 — — EP disclosed
EP-0535152-B1 Bis-benzo or benzopyrido cyclo hepta piperidene, piperidylene and piperazine compounds as PAF antagonists and compositions thereof. SCHERING CORP (US) 1995-08-09 — — EP disclosed
US-5422351-A Antiallergens; antiinflammatory agents SCHERING CORPORATION (US) 1995-06-06 — — US disclosed
WO-1995010516-A1 TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES SCHERING CORPORATION (US) 1995-04-20 — — WO disclosed
EP-0396083-B1 Heterocyclic N-oxide derivatives of substituted benzo[5,6]cycloheptapyridines, compositions and methods of use SCHERING CORP (US) 1994-11-30 — — EP disclosed
EP-0535152-A1 BIS-BENZO OR BENZOPYRIDO CYCLO HEPTA PIPERIDENE, PIPERIDYLIDENE AND PIPERAZINE COMPOUNDS AND COMPOSITIONS. SCHERING CORP (US) 1993-04-07 — — EP disclosed
US-5151423-A Antiinflammatory agents or antiallergens SCHERING CORPORATION (US) 1992-09-29 — — US disclosed
EP-0471750-A1 HETEROCYCLIC N-OXIDE DERIVATIVES OF SUBSTITUTED BENZO 5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE SCHERING CORPORATION (US) 1992-02-26 — — EP disclosed
WO-1992000293-A1 BIS-BENZO OR BENZOPYRIDO CYCLO HEPTA PIPERIDENE, PIPERIDYLIDENE AND PIPERAZINE COMPOUNDS AND COMPOSITIONS SCHERING CORPORATION (US) 1992-01-09 — — WO disclosed
WO-1990013548-A1 HETEROCYCLIC N-OXIDE DERIVATIVES OF SUBSTITUTED BENZO[5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE SCHERING CORPORATION (US) 1990-11-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055065-A1 Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases RASGRP1, CCNA1, CCNA2 FNTA 516/4885FNTB 1222/4885HRH1 389/4885
US-20020068742-A1 Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases RASGRP1, CCNA1, CCNA2 FNTA 516/4885FNTB 1222/4885HRH1 389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.